Authors: Sharon Salt (Editor)
Final Appraisal Determination for Aimovig® (erenumab) issued by NICE
Novartis (Frimley, UK) has announced that Aimovig® (erenumab) has not been recommended by NICE for the treatment of migraines. According to the company, the decision is particularly disappointing as NICE has recognized the clinical effectivness and tolerability of erenumab for chronic migraines and there remains an unmet need for effective and well-tolerated preventive migraine treatments in the UK.
At present, Botox® is approved by NICE for chronic migraine, however, the drug may not be suitable for all individuals who are living with migraine as it requires repeated visits to the clinic or multiple injections into the head and neck. In contrast, erenumab can be self-administered at home and doesn’t require routine visits to the clinic.
“We’re very disappointed that [NICE] has not recommended Aimovig (erenumab) for use on the National Health Service (NHS). Clearly this is not the result we’ve been working towards; with chronic migraine patients in England who could benefit from Aimovig being denied routine access to this important treatment option, whilst it is NHS funded in Scotland,” concluded Haseeb Ahmad, Managing Director in the UK, Ireland and Nordics of Novartis.
NICE issues draft guidance against Aimovig® (erenumab) for migraines
In January 2019, a draft guidance was issued by NICE (London, UK), which recommended against the routine NHS use of erenumab for the prevention of migraine in adults who experience at least four migraine days per month, and where at least three other preventive treatments haven’t worked.